Abstract
Background: In recent years, there has been an exponential increase in the global burden of cancer which has been associated with several factors including environmental influence, aging, diet, infectious agents, hormonal imbalance and chronic inflammation, among others. Cancerous cells utilize more glucose for its proliferation and survival than normal cells. Thus, the regulation of glucose consumption of cancerous cells through the inhibition of glucose transporter-4-protein (GLUT4) encoded by solute carrier family-2-member-4-gene (Slc2a4) by selected phytochemicals from Solanum xanthocarpum may serve as a new therapeutic candidate for the treatment of cancer.
Methods: The seven identified potential inhibitors of GLUT4 from Solanum xanthocarpum were retrieved from PubChem database. Examination of their drug-likeness, toxicity prediction and molecular docking studies of these compounds with GLUT4 were carried out using online tools such as Molinspiration, PreADMET V.2.0 and Patchdock server.
Results: The findings revealed that, five out of the seven compounds fulfil oral drugability of Lipinski’s rule of five (RO5) while two slightly meet the criteria of RO5. Conversely, five of the compounds are predicted to be mutagen while the remaining two are predicted to be safe for the body. Additionally, stigmasterol glucoside has higher binding-affinity (7590) with GLUT4 when compared to doxorubicin (6600) the control.
Conclusion: These findings suggest that stigmasterol glucoside from Solanum xanthocarpum could be a promising therapeutic agent with better therapeutic efficacy than doxorubicin in the treatment of cancer via the inhibition of GLUT4.
Keywords: GLUT4, cancer, Solanum xanthocarpum, drugability, stigmasterol glucoside, docking studies.
Graphical Abstract
[1]
Adekiya TA, Aruleba RT, Khanyile S, Masamba P, Oyinloye BE, Kappo AP. Structural analysis and epitope prediction of mhc class-1-chain related Protein-A for cancer vaccine development. Vaccines 2018; 6: 1.
[2]
Cao B, Bray F, Beltrán-Sánchez H, Ginsburg O, Soneji S, Soerjomataram I. Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981-2010. BMJ 2017; 357: j2765.
[3]
Hoekstra HJ, Wobbes T, Heineman E, Haryono S, Aryandono T, Balch CM. Fighting global disparities in cancer care: A surgical oncology view. Ann Surg Oncol 2016; 23: 2131-6.
[4]
Islam SM, Purnat TD, Phuong NTA, Mwingira U, Schacht K, Fröschl G. Non‐Communicable Diseases (NCDs) in developing countries: a symposium report. Global Health 2014; 10: 81.
[5]
Are C, Wong S, Leon A. Global cancer surgery, or lack therof: A wake-up call. Ann Surg Oncol 2016; 23: 1-3.
[6]
Lin SR, Fu YS, Tsai MJ, Cheng H, Weng CF. Natural compounds from herbs that can potentially execute as autophagy inducers for cancer therapy. Int J Mol Sci 2017; 18: 1412.
[8]
Zhang G, Liu Z, Qin S, Li K. Decreased expression of SIRT6 promotes tumor cell growth correlates closely with poor prognosis of ovarian cancer. Eur J Gynaecol Oncol 2015; 36: 629-32.
[9]
Gupta A, Chaphalkar SR. Cancer - constricting mankind from top 5 killer diseases. Micro Medicine 2015; 3: 36-44.
[10]
Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010; 29: 405-34.
[12]
Burney IA, Al-Moundhri MS. Major advances in the treatment of cancer: What does a non-oncologist need to know? Sultan Qaboos Univ Med J 2008; 8: 137-48.
[13]
Vishnuvarthan VJ, Lakshmi KS, Srividya AR. In-Silico screening of flavonoids targeted for death receptors in cancer by using hex molecular docking. J Young Pharm 2017; 9: 168-71.
[14]
Da Silva CG, Peters GJ, Ossendorp F, Cruz LJ. The potential of multi-compound nanoparticles to bypass drug resistance in cancer. Cancer Chemother Pharmacol 2017; 80: 881-94.
[15]
Aruleba RT, Adekiya TA, Oyinloye BE, Kappo AP. Structural Studies of Predicted Ligand Binding Sites and Molecular Docking Analysis of Slc2a4 as a Therapeutic Target for the Treatment of Cancer. Int J Mol Sci 2018; 19: 386.
[16]
Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4e532
[17]
Calvo MB, Figueroa A, Pulido EG, Campelo RG, Aparicio LA. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol 2010; 2010205357
[18]
Swain SS, Padhy RN. In vitro antibacterial efficacy of plants used by an Indian aboriginal tribe against pathogenic bacteria isolated from clinical samples. J Taibah Univ Med Sci 2015; 10: 379-90.
[19]
Kim S, Thiessen PA, Bolton EE, et al. PubChem substance and compound databases. Nucleic Acids Res 2015; 44: D1202-13.
[20]
Jayaram B, Singh T, Mukherjee G, Mathur A, Shekhar S, Shekhar V. Sanjeevini: A freely accessible web-server for target directed lead molecule discovery. BMC Bioinformatics 2012; 13: S7.
[21]
Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 2004; 1: 337-41.
[22]
Lee SK, Lee IH, Kim HJ, Chang GS, Chung JE, No KT. The PreADME Approach: Web-based program for rapid prediction of physico-chemical, drug absorption and drug-like properties EuroQSAR 2002 Designing drugs and crop protectants: processes, problems and solutions. Blackwell Publishing; Boston, Massachusetts 2003; pp. 418-20.
[23]
Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 2005; 33: W363-7.
[24]
Biovia DS. BIOVIA Discovery Studio Visualizer, v16 10 15350. San Diego: Dassault Systemes 2015. [cited: 2017 Mar 20]
[25]
Wei C, Bajpai R, Sharma H, et al. Development of GLUT4-selective antagonists for multiple myeloma therapy. Eur J Med Chem 2017; 139: 573-86.
[26]
Mishra RK, Wei C, Hresko RC, et al. In silico modeling-based identification of glucose transporter 4 (GLUT4)-selective inhibitors for cancer therapy. J Biol Chem 2015; 290: 14441-53.
[27]
Yan X, Qi M, Li P, Zhan Y, Shao H. Apigenin in cancer therapy: Anti-cancer effects and mechanisms of action. Cell Biosci 2017; 7: 50.
[28]
Yen GC, Chen CS, Chang WT, et al. Antioxidant activity and anticancer effect of ethanolic and aqueous extracts of the roots of Ficus beecheyana and their phenolic components. J Food Drug Anal 2018; 26: 182-92.
[29]
Nawab K, Yunus M, Mahdi AA, Gupta S. Evaluation of Anticancer Properties of Medicinal Plants from the Indian Sub-Continent. Mol Cell Pharmacol 2011; 3: 21-9.
[30]
Pitchai D, Roy A, Ignatius C. In vitro evaluation of anticancer potentials of lupeol isolated from Elephantopus scaber L. on MCF-7 cell line. J Adv Pharm Technol Res 2014; 5: 179-84.
[31]
Seo EJ, Saeed M, Law BY, et al. Pharmacogenomics of scopoletin in tumor cells. Molecules 2016; 21: 496.
[32]
Koduru S, Grierson DS, van de Venter M, Afolayan AJ. Anticancer activity of steroid alkaloids isolated from Solanum aculeastrum. Pharm Biol 2007; 45: 613-8.
[33]
Grattan BJ. Plant sterols as anticancer nutrients: Evidence for their role in breast cancer. Nutrients 2013; 5: 359-87.
[34]
El Shoubaky GA, Abdel-Daim MM, Mansour MH, Salem EA. Isolation and identification of a flavone Apigenin from marine red alga Acanthophora spicifera with antinociceptive and anti-inflammatory activities. J Exp Neurosci 2016; 10: 21-9.
[35]
Li YX, Qiao WT, Yuan K. Isolation and structure elucidation of chemical constituents of Mussaenda hainanensis Merr. J Med Plants Res 2011; 5: 1459-65.
[36]
Ye JC, Hsiao MW, Hsieh CH, Wu WC, Hung YC, Chang WC. Analysis of caffeic acid extraction from Ocimum gratissimum Linn. by high performance liquid chromatography and its effects on a cervical cancer cell line. Taiwan J Obstet Gynecol 2010; 49: 266-71.
[37]
Sawale JA, Patel JR, Kori ML. Isolation and characterization of oleonolic acid and lupeol from Vitex negundo leaves. J Pharmacogn Phytochem 2017; 6: 936-8.
[38]
Khan NMMU, Hossain MS. Scopoletin and β-sitosterol glucoside from roots of Ipomoea digitata. J Pharmacogn Phytochem 2015; 4: 5-7.
[39]
Jayakumar K, Murugan K. Purified solasodine from Solanum mauritianum Scop. And its molecular mechanism of antimetastatic potential. J Phytopharmacol 2017; 6: 251-9.
[40]
Ridhay A, Noor A, Soekamto NH, Harlim T, van Altena I. A stigmasterol glycoside from the root wood of Melochia umbellata (Houtt) Stapf var. degrabrata K. Indones J Chem 2012; 12: 100-3.
[41]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
[42]
Kazius J, McGuire R, Bursi R. Derivation and validation of toxicophores for mutagenicity prediction. J Med Chem 2005; 48: 312-20.
[43]
Maron DM, Ames BN. Revised methods for the salmonella mutagenicity test. Handbook of Mutagenicity Test Procedures 2012; p. 93.
[44]
Zhang C, Vasmatzis G, Cornette JL, DeLisi C. Determination of atomic desolvation energies from the structures of crystallized proteins. J Mol Biol 1997; 267: 707-26.
[45]
de Freitas RF, Schapira M. A systematic analysis of atomic protein-ligand interactions in the PDB. MedChemComm 2017; 8: 1970-81.
[46]
Kasahara Y, Kumaki K, Katagiri S, et al. Carthami flos extract and its component, stigmasterol, inhibit tumour promotion in mouse skin two-stage carcinogenesis. Phytother Res 1994; 8: 327-31.
[47]
Gao Z, Maloney DJ, Dedkova LM, Hecht SM. Inhibitors of DNA polymerase β: Activity and mechanism. Bioorganic Med Chem 2008; 16: 4331-40.
[48]
Lim JC, Park JH, Budesinsky M, et al. Antimutagenic constituents from the thorns of Gleditsia sinensis. Chem Pharm Bull 2005; 53: 561-4.
[49]
Kim YS, Li XF, Kang KH, Ryu B, Kim SK. Stigmasterol isolated from marine microalgae Navicula incerta induces apoptosis in human hepatoma HepG2 cells. BMB Rep 2014; 47: 433.
[50]
Luo X, Su P, Zhang W. Advances in microalgae-derived phytosterols for functional food and pharmaceutical applications. Mar Drugs 2015; 13: 4231-54.
[51]
Christodoulou MI, Kontos CK, Halabalaki M, Skaltsounis AL, Scorilas A. Nature promises new anticancer agents: interplay with the apoptosis-related BCL2 gene family. Anticancer Agents Med Chem 2014; 14: 375-99.
[52]
Gonza’lez-Medina M, Prieto-Martínez FD, Naveja JJ, et al. Chemoinformatic expedition of the chemical space of fungal products. Future Med Chem 2016; 8: 1399-412.
[53]
Stratton CF, Newman DJ, Tan DS. Cheminformatic comparison of approved drugs from natural product versus synthetic origins. Bioorg Med Chem Lett 2015; 25: 4802-7.
[54]
Kaneko T, Tahara S, Takabayashi F, Harada N. Inhibitory effect of esculin on oxidative DNA damage and carcinogenesis induced by N-nitrosobis(2-oxopropyl)amine in hamster pancreas. Biofactors 2004; 22: 83-5.
Article Metrics
38
8
2